IRON CHELATION AND VITAMIN-D3 IN COMBINATION WITH AZACITIDINE IMPROVES TREATMENT RESPONSE IN 19 HIGH RISK MYELODYSPLASTIC SYNDROMES AFTER AZACITIDINE FAILURE

被引：0
|
作者：
Brechemier, D. [1 ]
Comont, T. [1 ]
Bertoli, S. [2 ]
Dutertre, M. [1 ]
Recher, C. [2 ]
Adoue, D. [1 ]
Beyne-Rauzy, O. [1 ]
机构：
[1] Inst Univ Canc Toulouse Oncopole, Internal Med, Toulouse, France
[2] Inst Univ Canc Toulouse Oncopole, Hematol, Toulouse, France
来源：
LEUKEMIA RESEARCH | 2015年 / 39卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
91
引用
收藏
页码：S46 / S46
页数：1
相关论文
共 50 条
  • [1] IRON CHELATION THERAPY IMPROVES HAEMATOLOGICAL RESPONSE IN HIGH-RISK MYELODYSPLASTIC PATIENTS TREATED WITH AZACITIDINE
    Improta, S.
    Della Cioppa, P.
    Esposito, M.
    Gagliardi, A.
    Lucania, A.
    Izzo, G. Nitrato
    Villa, M. R.
    Mastrullo, L.
    LEUKEMIA RESEARCH, 2015, 39 : S52 - S53
  • [2] IRON CHELATION THERAPY IMPROVES HAEMATOLOGICAL RESPONSE IN HIGH-RISK MYELODYSPLASTIC PATIENTS TREATED WITH AZACITIDINE
    Villa, M. R.
    Gagliardi, A.
    Della Cioppa, P.
    Esposito, M.
    Lucania, A.
    Izzo, G. Nitrato
    Improta, S.
    Mastrullo, L.
    HAEMATOLOGICA, 2016, 101 : S120 - S121
  • [3] IRON CHELATION THERAPY IMPROVES HAEMATOLOGICAL RESPONSE IN HIGH-RISK MYELODYSPLASTIC PATIENTS TREATED WITH AZACITIDINE
    Improta, S.
    Della Cioppa, P.
    Lucania, A.
    Esposito, M.
    Mastrullo, L.
    HAEMATOLOGICA, 2015, 100 : 103 - 104
  • [4] IRON CHELATION THERAPY IMPROVES HAEMATOLOGICAL RESPONSE IN HIGH-RISK MYELODYSPLASTIC PATIENTS TREATED WITH AZACITIDINE
    Improta, S.
    Villa, M. R.
    Della Cioppa, P.
    Lucania, A.
    Esposito, M.
    Izzo, G. Nitrato
    Gagliardi, A.
    Mastrullo, L.
    HAEMATOLOGICA, 2017, 102 : 766 - 767
  • [5] Treatment with Oral Azacitidine in Elderly Patients with Higher Risk Myelodysplastic Syndromes after Response to Subcutaneous Azacitidine
    Santini, Valeria
    Amato, Cristina
    Caciagli, Barbara
    Consagra, Angela
    Rigodanza, Luca
    de Pourcq, Sven
    Cassari, Margherita
    Tofacchi, Elena
    Mattiuz, Giorgio
    Raddi, Marco Gabriele Gabriele
    Sanna, Alessandro
    BLOOD, 2022, 140 : 12313 - 12314
  • [6] Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure
    Prebet, Thomas
    Gore, Steven D.
    Esterni, Benjamin
    Gardin, Claude
    Itzykson, Raphael
    Thepot, Sylvain
    Dreyfus, Francois
    Rauzy, Odile Beyne
    Recher, Christian
    Ades, Lionel
    Quesnel, Bruno
    Beach, C. L.
    Fenaux, Pierre
    Vey, Norbert
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (24) : 3322 - 3327
  • [7] Azacitidine and Venetoclax Combination for Upfront Treatment of Higher-Risk Myelodysplastic Syndromes
    Al Ali, Najla
    Sallman, David
    Chan, Onyee
    Padron, Eric
    Sweet, Kendra
    Kuykendall, Andrew
    Lancet, Jeffrey
    Komrokji, Rami
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S341 - S341
  • [8] HEMATOLOGIC RESPONSE TO AN ALTERNATIVE DOSING SCHEDULE OF AZACITIDINE IN HIGH-RISK MYELODYSPLASTIC SYNDROMES
    Finelli, C.
    Clissa, C.
    y Follo, M.
    Curti, A.
    Paolini, S.
    Papayannidis, C.
    Testoni, N.
    Ottaviani, E.
    Parisi, S.
    Martinelli, G.
    Cocco, L.
    Baccarani, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 560 - 560
  • [9] Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine
    Duong, Vu H.
    Bhatnagar, Bhavana
    Zandberg, Dan P.
    Vannorsdall, Emily J.
    Tidwell, Michael L.
    Chen, Qing
    Baer, Maria R.
    LEUKEMIA & LYMPHOMA, 2015, 56 (06) : 1718 - 1722
  • [10] The effects of continued azacitidine treatment cycles on response in higher risk patients with myelodysplastic syndromes: an update
    Silverman, L. R.
    Fenaux, P.
    Mufti, G. J.
    Santini, V.
    Hellstrom-Lindberg, E.
    Gattermann, N.
    Sanz, G.
    List, A. F.
    Gore, S. D.
    Seymour, J. F.
    Backstrom, J.
    McKenzie, D.
    Beach, C. L.
    ECANCERMEDICALSCIENCE, 2008, 2
12345